For research use only. Not for therapeutic Use.
Rifapentine (DL 473) is an antibiotic used in tuberculosis research[1].
Rifapentine shows antibacterial activity against clinical staphylococci, with MICs ranging from 0.002 to >10 μg/mL (MIC90 values of 1.28 μg/mL for MSSA and MSSE, and ≥10 μg/mL for MRSA and MRSE)[3].
Rifapentine (20 mg/kg, i.p., daily for five days followed by twice weekly for three weeks) reduces bacteria burden in the organs of a mouse model of disseminated Mycobacterium avium infection[2].
Rifapentine (a single dose of 30 mg/kg, i.v.) shows a plasma Cmax, T1/2 and AUC0-15 were 33 µg/mL (0.5 h), 4 h and 170 µg h/mL in rabbits. In lung tissue, the Cmax, T1/2 and AUC0-15 are 13 µg/mL (2 h), 6.7 h and 82 µg h/mL[4].
| Catalog Number | I046396 |
| CAS Number | 61379-65-5 |
| Synonyms | [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21E)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
| Molecular Formula | C47H64N4O12 |
| Purity | ≥95% |
| InChI | InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14+,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1 |
| InChIKey | WDZCUPBHRAEYDL-QEDJKGLXSA-N |
| SMILES | CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C |
| Reference | [1]. Sharma, S.K., et al., Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev, 2013. 7: p. CD007545. [2]. Klemens SP, et al. Activity of rifapentine against Mycobacterium avium infection in beige mice. J Antimicrob Chemother. 1992 May;29(5):555-61. [3]. Albano M, et al. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. Antimicrob Agents Chemother. 2019 Oct 22;63(11):e00959-19. [4]. Rifat D, et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci Transl Med. 2018 Apr 4;10(435):eaai7786. |
